LMR-123

LMR-123 is a neuroprotective therapeutic candidate that was developed by Medical Industries Australia (also known as Australia Medical Industries) for the treatment of acute ischemic stroke. The drug was designed to mitigate neuronal damage following a stroke, potentially by serving as a substrate for nitric oxide synthase (NOS) to enhance nitric oxide production, thereby promoting vasodilation and improving microvascular perfusion in the ischemic penumbra. In 2011, LMR-123 entered a Phase 1 clinical trial (ACTRN12611000544910), which was a randomized, double-blind, placebo-controlled, single ascending dose study conducted in healthy volunteers to evaluate its safety, tolerability, and pharmacokinetics via intravenous infusion. Despite completing the initial safety assessment, no further clinical development has been documented in public registries or company pipelines, and the program is currently considered discontinued.